San Diego-based biotech Aspen Neuroscience has filed with the SEC to raise up to $100 million in an initial public offering.
Aspen’s lead investigational product, sasineprocel, is an iPSC-based cell therapy being evaluated for the treatment of Parkinson’s Disease.
Sasineprocel was granted RMAT designation in August, based on results from the ongoing phase 1/2a ASPIRO trial, which has demonstrated encouraging early clinical activity and a favorable safety profile. The study is an open-label, multicohort, multicenter trial evaluating the safety, tolerability and activity of the surgical delivery of autologous dopaminergic neuron precursor cells (DANPCs) into the putamen, the part of the brain where restoration of dopamine signaling is needed.
Aspen’s personalized approach means that patients do not require immunosuppressive (IS) drugs to dampen the body’s immune response against foreign cells, which can help avoid IS‑associated adverse events, eliminate IS drug‑monitoring requirements, and enable dosing for those with contraindications to IS therapies.
The biotech anticipates dosing patients in a phase 3 trial for sasineprocel in the second half of 2027.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!